Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Xalkori
(United States) [Available]Synonyms :
crizotinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor;
Brand Name :
Xalkori
(United States) [Available]Synonyms :
crizotinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor;
250
mg
Oral
twice a day
Continue the therapy until disease progression or unacceptable effects occur.
280
mg
Capsule
Orally
twice a day
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the effect of flibanserin by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in the effect of crizotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in levels of lomitapide by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib can impact the hepatic/intestinal enzyme CYP3A4 metabolism, leading to an elevation in the level or potency of intranasal midazolam
it may enhance the qtc interval when combined with lofexidine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of crizotinib
midostaurin and crizotinib, when used simultaneously, increase the QTc level
midostaurin and crizotinib, when used simultaneously, increase the QTc level
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in QTC interval
when both drugs are combined, there may be an increase in QTC interval
it may enhance the metabolism when combined with oxcarbazepine
Combining tegafur with crizotinib can reduce tegafur’s metabolism
When alprazolam and crizotinib is used together, this leads to reduction in the alprazolam’s metabolism
crizotinib: they may enhance the serum concentration of CYP3A4 Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A4 Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A4 Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A4 Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A4 Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A Inhibitors
When ponesimod is used together with crizotinib, this leads to enhanced risk or seriousness of bradycardia
When crizotinib is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When crizotinib is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
When crizotinib is used together with oleandomycin, this leads to enhanced concentration serum of crizotinib
When crizotinib is used together with ridaforolimus, this leads to enhanced concentration serum of crizotinib
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
QTc interval is increased both by lenvatinib and crizotinib
the effect of crizotinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, both increase the QTC interval
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
may enhance serum level and toxicity of docetaxel
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
When crizotinib is used together with oliceridine, this leads to enhanced concentration serum of oliceridine
when both drugs are combined, there may be an increase in QTC interval
when both drugs are combined, there may be an increase in QTC interval
Crizotinib is a tyrosine kinase receptor inhibitor that targets Recepteur d’Origine Nantais (RON), hepatocyte growth factor receptor (HGFR, c-MET), and anaplastic lymphoma kinase (ALK).
ALK-positive tumors occur in a small percentage of patients with non-small cell lung cancer (NSCLC). ALK’s fusion with the chimeric protein echinoderm microtubule-associated protein-like 4 (EML4) is a characteristic of most of these cases.
ALK is inhibited by crizotinib through the creation of an inactive protein structure and the inhibition of its phosphorylation. Tumor survival and cell proliferation with this genetic mutation are reduced.
Adverse drug reactions:
Frequency defined
>10%
Upper respiratory infection
Neutropenia
lymphopenia
leukopenia
Anemia
Dysgeusia
dizziness
balance disorder
dizziness
dizziness postural
presyncope
neuropathy
0.1-1%:
QT interval prolongation
Cardiac failure congestive
ejection fraction decreased
left ventricular failure
pulmonary edema
Syncope
Hepatic failure
increased gamma-glutamyl transferase
Febrile neutropenia
Pulmonary embolism
interstitial lung disease
Renal cyst
None
Contraindication:
None
Caution:
Drug-induced hepatoxicity
Symptomatic bradycardia
Visual loss
Gastrointestinal toxicity
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
In a phase I trial, 50–300 mg of crizotinib were administered daily or twice daily to 37 patients with a range of solid tumor malignancies that were not responding to treatment. Two patients with non-small cell lung cancer (NSCLC) in this cohort responded to treatment after developing mutations in the anaplastic lymphoma kinase (ALK) gene linked to echinoderm microtubule-associated protein-like 4 (EML4).
The two-year overall survival rate was higher for ALK mutation-positive patients treated with crizotinib than for those who did not receive the medication.
It is taken orally in tablet form with or without food.
It should be swallow as whole at time.
Don’t chew or crush the pellets.
Pellets enclosed in a shell should not be swallowed.
After 6 hours, skip the missing dose and don’t take two doses to make up for it.
Do not take an additional dose if you vomited after taking it; instead, take it at the appointed time.
Patient information leaflet
Generic Name: crizotinib
Why do we use crizotinib?
A kinase inhibitor called crizotinib is prescribed to patients with metastatic non-small cell lung cancer (NSCLC) whose tumors test positive for ROS1 or anaplastic lymphoma kinase (ALK) according to an FDA-approved test.
In pediatric patients aged 1 year and up, as well as young adults, crizotinib is also recommended for the treatment of recurrent or refractory systemic anaplastic large cell lymphoma (ALCL).
Patients aged one year and up who have an inflammatory myofibroblastic tumor (IMT) that is unresectable, recurrent, or resistant may be treated with crizotinib.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
